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Unravelling the GSK3β-related genotypic interaction network
influencing hippocampal volume in recurrent major
depressive disorder
Becky Inkstera,b,c, Andy Simmonsd, James H. Coled,e, Erwin Schoofj,
Rune Lindingj, Tom Nicholsg, Pierandrea Mugliam, Florian Holsboerl,
Philipp G. Sämannl, Peter McGuffind, Cynthia H.Y. Fud, Kamilla Miskowiakk,
Paul M. Matthewsf, Gwyneth Zain,o and Kristin Nicodemush,i
Objective Glycogen synthase kinase 3β (GSK3β) has been
implicated in mood disorders. We previously reported
associations between a GSK3β polymorphism and
hippocampal volume in major depressive disorder (MDD).
We then reported similar associations for a subset of
GSK3β-regulated genes. We now investigate an algorithm-
derived comprehensive list of genes encoding proteins that
directly interact with GSK3β to identify a genotypic network
influencing hippocampal volume in MDD.
Participants and methods We used discovery (N=141)
and replication (N=77) recurrent MDD samples. Our gene
list was generated from the NetworKIN database.
Hippocampal measures were derived using an optimized
Freesurfer protocol. We identified interacting single nucleotide
polymorphisms using the machine learning algorithm
Random Forest and verified interactions using likelihood
ratio tests between nested linear regression models.
Results The discovery sample showed multiple two-single
nucleotide polymorphism interactions with hippocampal
volume. The replication sample showed a replicable interaction
(likelihood ratio test: P=0.0088, replication sample; P=0.017,
discovery sample; Stouffer’s combined P=0.0007) between
genes associated previously with endoplasmic reticulum
stress, calcium regulation and histone modifications.
Conclusion Our results provide genetic evidence supporting
associations between hippocampal volume and MDD, which
may reflect underlying cellular stress responses. Our study
provides evidence of biological mechanisms that should be
further explored in the search for disease-modifying therapeutic
targets for depression. Psychiatr Genet 28:77–84 Copyright ©
2018 The Author(s). Published by Wolters Kluwer Health, Inc.
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Introduction
Glycogen synthase kinase 3β (GSK3β; OMIM 605004) is
a unique pleiotropic protein kinase. It was originally
identified for its function involving glycogen synthesis
(Embi et al., 1980), but it is now recognized for playing
multiple cellular roles in metabolism, transcription,
apoptosis, neurogenesis, cell survival, neural differentia-
tion, immune responses, neurotransmitter function and
synaptic plasticity (Grimes and Jope, 2001; Kim and
Snider, 2011; Beurel et al., 2015; Gao et al., 2016).
GSK3β inhibition has been implicated as a biological
mechanism of mood regulation (Li and Jope, 2010),
mood stabilizers, antidepressants (Beaulieu, 2012) and
treatment-resistant depression (Costemale-Lacoste et al.,
2016). Behavioural studies have shown that GSK3β reg-
ulates depressive-like behaviours and memory function
(Pardo et al., 2016), hippocampal plasticity in maternal
separation models (Bian et al., 2015) and models of
behavioural despair (Strekalova et al., 2016).
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We previously carried out brain-wide analyses that
identified associations between hippocampal volume and
a functional GSK3β polymorphism (rs6438552) in major
depressive disorder (MDD) patients (Inkster et al., 2009).
We subsequently reported brain structural associations
with a subset of genes that biologically interact with
GSK3β (Inkster et al., 2010).
We now examine a comprehensive list of genes that
encode proteins that directly interact with GSK3β. We
focused on the right hippocampal volume as the pheno-
type because of previous, region-specific results in the right
hippocampus of gene-by-MDD effects of GSK3b-related
and several canonical Wnt signalling pathway-related single
nucleotide polymorphisms (SNPs) (Inkster et al., 2009,
2010). Independent of this, the same segmentation tech-
nique as that applied here has been used widely in large-
scale imaging genetic studies on the hippocampus (Hibar
et al., 2015, 2017) and in prospective meta-analyses on
MDD (Schmaal et al., 2016). Our aim is to identify a
GSK3β-related genotypic interaction network influencing
hippocampal volume in MDD patients using machine
learning methods (Nicodemus et al., 2010a, 2010b) applied
to discovery and replication samples (Cohen-Woods et al.,
2009; Inkster et al., 2009).
Participants and methods
The discovery sample
Major depressive disorder patients
The discovery sample included 145 patients with recur-
rent MDD described in detail elsewhere (Inkster et al.,
2009, 2010). In brief, MDD patients belonged to a cohort
of 1022 recurrent MDD patients and 1000 healthy con-
trols (Tozzi et al., 2008). The recruiting hospital obtained
approval from the Research Ethical Board. Patients were
assessed primarily at the Max Planck Institute of
Psychiatry, Munich, Germany. Patients with bipolar dis-
order, mood incongruent psychotic symptoms, a lifetime
history of drug use or diagnosis of drug dependency,
depression secondary to alcohol or substance abuse or
depression as a result of medical illnesses or use of
medications were not included in the study. Age and sex
demographics are summarized in Table 1.
Structural brain imaging
MRI acquisition
High-resolution T1-weighted MRIs were acquired on a
1.5-T General Electric scanner (Signa, later upgraded to
Signa Excite; Waukesha, Wisconsin, USA), inversion recov-
ery prepared spoiled gradient echo recalled with a field-of-
view of 22×22 cm2, a matrix of 256×256, 124 sagittal slices
and a resulting voxel size of (1.2−1.4) 0.9×0.9mm3 (time to
repetition, 10.3ms; echo time, 3.4ms; flip angle 20°).
FreeSurfer
We used FreeSurfer (http://surfer.nmr.mgh.harvard.edu) to
create an optimized protocol to derive right hippocampal
volume measures. The recon-all command was used to
process each T1 image. This process involves the removal
of nonbrain tissue using a hybrid watershed/surface defor-
mation procedure, intensity normalization, automated
transformation to the Talairach atlas and segmentation of
the subcortical grey matter nuclei.
Image quality control
The sample originally included 193 patients. Previous
quality control (QC) procedures reduced this number to
145 (detailed in Inkster et al., 2009). In this study,
FreeSurfer images were inspected visually to ensure
accuracy of registration and segmentation procedures. The
sample was reduced to 141 [three patients were excluded
with ± 3 SD and one with a missing value for the covariate,
intracranial volume (ICV)]. The QC measures that we
applied were consistent across the discovery and replica-
tion samples. We did, however, observe a difference in the
percentage of participants lost to QC across the two cohorts
(~26% in the discovery sample vs. 10% in the replication
sample). This could be related to site-specific participant-
related issues (i.e. increased head motion at this site) or
differences in the scanner data collection process or soft-
ware packages used, etc.
The replication sample
Major depressive disorder patients
The replication sample included 77 recurrent MDD patients
recruited at the Institute of Psychiatry, Psychology and
Neuroscience, King’s College London, UK. Patients had
previously participated in genetic association studies (Uher
et al., 2008; Cohen-Woods et al., 2009) and imaging genetics
studies (Cole et al., 2011, 2013). The Bexley and Greenwich
NHS Research Ethics Committee approved this study.
Patients had experienced two or more depressive episodes of
at least moderate severity, separated by at least 2 months of
remission. The diagnosis was made using the Schedules for
Clinical Assessment in Neuropsychiatry interview (Wing
et al., 1990) according to theDiagnostic and Statistical Manual of
Mental Disorders, 4th ed. (DSM-IV) criteria. Exclusions were
made if the patient, or a first-degree relative, ever fulfilled the
Table 1 Demographics for the discovery and replication imaging
genetics samples
Samples Discovery Replication
N 141 69
Right hippocampal volume
[mean (SD)]
4150.8 (387.7) 3950.7 (473.8)*
Female [n (%)] 86 (61.0) 48 (69.6)
Age [mean (SD)] 49.2 (13.3) 48.5 (8.1)
ICV (SD) 1 506 774 (160739) 1 473 184 (235 564)
MRI coil upgrade [n (%)] 36 (25.5) NA
ICV, intracranial volume; NA, not available.
*The mean right hippocampal volume was significantly larger in the discovery
sample versus the replication sample (t-test, P=0.0029). No other significant
differences were observed (all P>0.05, uncorrected). We did not analyse anti-
depressant medication effects because of missing data across samples and
because of the large heterogeneity in medications used.
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criteria for mania, hypomania, schizophrenia or mood incon-
gruent psychosis, had a diagnosis of any neurological disorder
or other condition known to affect brain structure or function.
Other exclusion criteria included a lifetime diagnosis of
alcohol or substance abuse, depression only secondary to
medical illness or medication, a diagnosis of mania or psy-
chosis in first-degree or second-degree relatives or a contra-
indication to MRI. Age and sex demographic details are
described in Table 1.
Structural brain imaging
MRI acquisition, freesurfer and image quality control
Magnetization-Prepared Rapid Gradient Echo T1-weighted
scans were collected at the Institute of Psychiatry, King’s
College London, on a 1.5T Signa HDx system (General
Electric, Boston, Massachusetts, USA). Acquisition para-
meters were as follows: echo time=3.8ms, repetition
time=8.59ms, flip angle=8°, field-of-view=24 cm×24
cm, slice thickness=1.2mm, number of slices=180 and
image matrix=256×256. We used the same FreeSurfer
protocol as that described in the discovery sample.
GSK3β network gene list
Our GSK3β gene network list (Supplementary Table S1,
Supplemental digital content 1, http://links.lww.com/PG/A206)
was derived using the NetworKIN algorithm from Linding
et al. (2007); http://networkin.lindinglab.org, which integrates
consensus substrate motifs (NetPhorest) with context
modelling (STRING) to improve the prediction of cellular
kinase–substrate relations (Linding et al., 2007). Gene
boundaries were as given in NCBI Gene and dbSNP.
Genetic data
The discovery sample
Whole-genome scan genotypes were obtained follow-
ing the QC procedures described elsewhere (Tozzi
et al., 2008; Muglia et al., 2010). In brief, genotypes
were obtained using two-channel signal intensity data,
corresponding to the two alleles at each SNP that were
evaluated using Beadstudio 3.1 (Illumina Inc., San
Diego, California, USA). The initial genotype calls
were generated using the cluster file. The whole-
genome association analysis of the full sample of
patients and controls produced a genomic control of
λ= 1002 (Muglia et al., 2010). The data were imputed as
part of the Psychiatric Genomics Consortium MDD
genome-wide association study to HapMap3 reference
sequence using the utah residents with northern and
western European ancestry from the CEPH collection
and Toscani in Italia populations. Of the 271 genes
in the network, we removed nonautosomal genes
(N= 9) and genes that contained no SNPs (N= 10)
(Supplementary Table 1, Supplemental digital content
1, http://links.lww.com/PG/A206). Gene boundaries were
as given in NCBI Gene and dbSNP. A total of 8846
SNPs were available in the 252 genes. Hard-called
genotypes from dosage data were used in the
interaction analyses, with a dosage hard call threshold of
0.8 using PLINK v1.0.7. Missing genotypes (missing-
ness range per individual= 1.3–3.5%) were imputed
using median imputation as the Random Forest (RF)
algorithm does not handle missing values. The Hardy–
Weinberg Equilibrium threshold P value was set to
0.001; none were removed. Before analysis with RF,
SNPs were linkage disequilibrium (LD)-pruned
(r2= 0.25) as strongly correlated predictors can influ-
ence the results of RF (Nicodemus and Malley, 2009;
Nicodemus et al., 2010c; Nicodemus, 2011), leaving a
total of 1155 SNPs for analysis.
The replication sample
Genotypes were derived from genome-wide microarray
data described elsewhere (Lewis et al., 2010). DNA
samples were genotyped using the Illumina Human-
Hap610-Quad BeadChips (Illumina Inc.) by the Centre
National de Genotypage (Evry, France). Patients were
excluded on the basis of missingness per individual greater
than 1% or abnormal heterozygosity. A single patient was
excluded if pairs of patients showed greater than second-
degree relatedness. SNPs were excluded if they showed a
departure from Hardy–Weinberg Equilibrium with a
P value less than 0.00001. Principal component analysis
was carried out using EIGENSTRAT (Price et al., 2006)
after QC procedures. Imputation was performed after using
LiftOver to map SNPs from hg18 to hg19 coordinates and
then the Genotype Harmonizer (Deelin et al., 2014) was
used to prepare the genotypes for imputation through
alignment to the Haplotype Reference Consortium
(McCarthy et al., 2016). Phasing and imputation were
completed on the Michigan imputation server (Das et al.,
2016) using the Haplotype Reference Consortium refer-
ence panel, version r1.1, phasing using Eagle v.2.3 (Loh
et al., 2016) with the EUR population. Of the 77 indivi-
duals, the following were excluded before analysis: two
after failing imaging QC, one with inconsistent sex-versus-
genotype data reported, one with non-European ancestry
and four after failing genotyping or imputation QC, leaving
69 for analysis.
Statistical analyses
Initial analysis of the discovery sample used standard
single SNP linear regression models on right hippo-
campal volume, controlling for age, sex, ICV and head
coil upgrade. The discovery sample analysis was carried
out using the machine learning algorithm RF (Breiman,
2001), which is designed for high-dimensional data sets,
and its variable importance measure, used here, captures
the main effects of single predictors as well as complex
interactions. This method has successfully identified
validated epistasis in the context of IQ in psychosis and
in schizophrenia case–control genomics data (Nicodemus
et al., 2010a, 2010b). To control for the effects of sex, age,
ICV and imaging head coil upgrade in the RF analysis,
we regressed these variables of noninterest out on both
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sides of the equation (right hippocampal volume and
SNPs) and used the residuals as input as described pre-
viously (Zhao et al., 2012). For the RF analysis, the
number of variables selected at each split of the tree
(mtry) was set to 300 and the number of trees constructed
per forest was 1000 (Fig. 1). We used the permutation-
based variable importance measure as a measure of
association between SNPs and outcome. To obtain stable
estimates of the variable importance measures, we re-ran
RF on the same data 1000 times, changing the random
number seed each time, and used the median of these
variable importance values as the final set of variable
importance measures (Nicodemus and Malley, 2009). We
re-ran the RF algorithm on 1000 sets of data in the dis-
covery sample where the outcome had been permuted
randomly to obtain a null distribution of variable impor-
tance measures for each SNP (Nicodemus, 2011) to
calculate an empirical P value. The empirical P value
associated with RF variable importance measures was
used to determine which SNPs would be tested for a two-
way interaction using likelihood ratio tests (LRT)
between nested linear regression models:
Fullmodel :Right hippocampal volume
 b1 ageþb2 sexþb3 ICVþb4
Head coil upgradeþb5 SNPi
þb6 SNPjþb7 SNPiSNPj:
Reducedmodel :Right hippocampal volume
 b1 ageþb2 sexþb3 ICVþb4
Head coil upgradeþb5 SNPiþb6 SNPj:
The 1000 null replicates were used to calculate an
empirical experiment-wise P value for the number of
significant LRTs out of the 300 possible two-way inter-
actions from the reduced list provided by RF. Replication
was attempted only for those models showing P values
less than 0.05 uncorrected. For the replication sample
analyses, linear regression models were used and LRTs
between nested models tested the significance of the
interaction, just as we had done above for the discovery
sample. The replication sample model included sex, age,
10 principal components to control for population strati-
fication and ICV as covariates. Only 19 SNPs from the
two-SNP interactions were available; of these, five two-
SNP interaction pairs were found where both SNPs were
available for analysis (rs12469994–rs2291862, rs12469994–
rs939626, rs2291862–rs1052751, rs11780700–rs1052751 and
rs939626–rs4387877).
Expression quantitative trait loci analysis
For all SNPs identified to be associated significantly with
hippocampal volume in the RF analysis, we carried
out an expression quantitative trait loci analysis using the
BRAINEAC database (Ramasamy et al., 2014). The
BRAINEAC database has a larger number of brain tissue
Fig. 1
Schema of Random Forest analysis. GSK, glycogen synthase kinase; LRT, likelihood ratio test; RF, Random Forest; SNP, single nucleotide
polymorphism.
80 Psychiatric Genetics 2018, Vol 28 No 5
samples than Genotype-Tissue Expression (Carithers
and Moore, 2015); in addition, BRAINEAC individuals
were confirmed to be of European descent, like our
sample, and also neuropathologically normal. In contrast,
Genotype-Tissue Expression individuals include those
who have neurological causes of death.
Healthy control sample analysis
Replicated interactions in the MDD samples were tested
for interaction with 147 healthy control participants
available from the discovery sample (Inkster et al., 2009)
using the same model and QC protocol. Overall, 153
healthy control participants were available originally for
analysis; three did not pass imaging QC, two had missing
covariate or genotype values and one was excluded
because their right hippocampal volume was greater than
3SDs from the mean of controls.
Results
Demographics
The mean right hippocampal volume was significantly
larger in the discovery sample versus the replication
sample (t-test, P= 0.0029). No other significant differ-
ences were observed (all P> 0.05, uncorrected). We did
not analyse antidepressant medication effects because
of missing data across samples and because of a large
heterogeneity in the medications used.
Discovery sample
No single SNP was associated significantly with right hip-
pocampal volume in the discovery sample (Supplementary
Table S2, Supplemental digital content 2, http://links.lww.com/
PG/A207). The most strongly associated single SNP
was rs7364220, an intronic variant in the gene PPARA
(P=6.36E−05; Bonferroni threshold=5.654E−06). RF
analysis showed 15 SNPs with empirical P values less than
0.05 (Table 2) that were then subjected to all possible two-
way interaction modelling using linear regression, controlling
for age, sex, head coil upgrade and ICV, resulting in 105 tests
in the discovery sample. Ten of the 15 of the RF-significant
SNPs also had single SNP P values less than 0.05, uncor-
rected, and all except one SNP were found to participate in
one to three two-SNP interactions using LRTs between
nested models (Supplementary Table S3, Supplemental
digital content 3, http://links.lww.com/PG/A208). Histone dea-
cetylase 4 (HDAC4) had two SNPs participating in interac-
tions. Although no two-SNP interaction LRT P value passed
correction for multiple testing (Bonferroni-corrected critical
value=0.00048), given 105 two-SNP interaction models, the
expected number of interactions with a LRT P value less
than 0.05 is 5.25; we observed 12 using our SNPs as identified
as significant with RF. This excess of LRT P values less than
0.05 was not because of SNPs in LD as SNPs were LD-
pruned before RF analysis. To obtain an experiment-wise
null distribution of the number of interactions with an LRT P
value less than 0.05, we re-ran all 105 two-SNP interactions
on 1000 null replicates where the phenotype had been
permuted without replacement using the same model as in
the analysis of the observed data. Twelve of the 1000 repli-
cates showed at least 12 interactions with an LRT P value
less than 0.05 (empirical experiment-wise P=0.012).
Replication sample
Five interaction models were taken forward for testing in
the replication sample. One interaction model was repli-
cated showing the same direction of effect. The model
included HDAC4 rs12469994 and ITPR1 rs2291862, the
most significant interaction in the original discovery sample.
Individuals who carried more copies of minor alleles at both
SNPs showed a significant decrease in hippocampal volume
in both the discovery and the replication samples (replica-
tion sample LRT P=0.0088, Δr2=0.027; and discovery
sample LRT P=0.017, Δr2=0.072). Combining P values
across the two independent samples using Stouffer’s Z
trend (which takes into account the individual P values, the
sample size and the direction of effect) led to a combined P
value of 0.0007 for the HDAC4–ITPR1 interaction.
Healthy control sample analysis
The replicated interaction in the MDD samples between
HDAC4 and ITPR1 was tested for interaction using 147
healthy control participants available from the discovery
sample (Inkster et al., 2009) using the same model and
QC protocol (see the Participants and Methods section
for details). The LRT between nested models, testing
for interaction effects, was not significant (P= 0.77). In
addition, the main effects for both SNPs were also not
significant in the full model or in the model with main
effects and no interaction term (all P> 0.83).
Expression quantitative trait loci analysis
Our analysis showed a significant association between
the SNP identified in our study, rs2291862, and ITPR1
Table 2 Random Forest-identified empirically significant single
nucleotide polymorphisms associated with right hippocampal
volume in major depressive disorder patients
SNPs
Single
SNP P
value
RF
empirical
P value
Two-SNP
interactions
(n) Gene Function
rs4844550 7.53E−05 0.044 2 MAPKAPK2 Upstream
variant
rs3791424 0.0081 0.021 1 HDAC4 Intron
rs12469994 0.003 0.014 2 HDAC4 Intron
rs2291862 0.012 0.02 2 ITPR1 Synonymous
rs13083813 0.14 0.017 2 TGFBR2 Intron
rs3798290 0.058 0.016 1 FHL5 Intron
rs4720279 0.0052 0.012 1 AMPH Intron
rs2058502 0.0044 0.003 2 EGFR Intron
rs11780700 0.034 0.034 2 C8orf44,
SGK3
Intron
rs11014511 0.0098 0.049 1 CACNB2 Intron
rs939626 0.089 0.01 2 IGF1R Intron
rs1052751 0.21 0.004 3 PLD2 Synonymous
rs11654719 0.0052 <0.001 1 PRKCA Intron
rs2279103 0.18 0.031 0 CTDP1 Missense
rs4387877 7.53E−05 0.002 2 PLCB1 Intron
Single SNP P values in italics indicate a negative association.
RF, Random Forest; SNP, single nucleotide polymorphism.
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hippocampal expression (P=0.0045) as well as the SNP,
rs12469994, associated with HDAC4 hippocampal gene
expression (P=0.017). We also observed that rs12469994
was related to ASB1 gene expression; however, it is unclear
as to how this relates to our findings. A full set of results can
be found in Supplementary Table 4 (Supplemental digital
content 4, http://links.lww.com/PG/A209).
Discussion
Our study aimed to identify a GSK3β-related genotypic
interaction network influencing hippocampal volume in
MDD using a comprehensive list of known proteins that
bind to GSK3β. Using two independent imaging genetics
recurrent MDD data sets, we confirmed a significant
genotypic interaction (with hippocampal volume) in
genes linked to endoplasmic reticulum (ER) stress, cal-
cium regulation and histone deacetylase modifications.
Our findings are important for several reasons. This is the
first psychiatric imaging genetics study to systematically
examine a comprehensive list of genes with direct bio-
logical GSK3β interactions. It is therefore the first
examination of putative genotypic combinations amongst
this network. We used a machine learning algorithm in
the discovery sample that explicitly models both genetic
main effects and interactions through creating recursively
partitioned trees. Given that these genes interact physi-
cally in this biological network, we hypothesized that an
epistatic effect may be present. We did not observe any
single SNP effects that were significant after multiple
testing, whereas we discovered and replicated a two-SNP
interaction between HDAC4 and ITPR1 that was asso-
ciated with decreased hippocampal volume among MDD
patients carrying putative ‘risk’ alleles at both SNPs.
Inositol 1,4,5-triphosphate receptor, type 1 (ITPR1; OMIM
147265), is a calcium channel that regulates the release of
calcium from the ER (Yamada et al., 1994). The ER con-
tains the largest reservoir of calcium in the cell. It is also
responsible for the correct folding of proteins before their
delivery into the cytoplasm. When the ER system is
stressed, a large amount of calcium is released into the
cytoplasm, which can lead to apoptosis. Our identification
of ITPR1 can be interpreted using the framework proposed
by Gold et al. (2013), suggesting that impaired ER stress
responses play a role in depression. Our study adds to the
literature of genetic associations with ER stress and mood
disorders (Kakiuchi et al., 2003, 2007; Grunebaum et al.,
2009; Hayashi et al., 2009; Nevell et al., 2014), in particular,
the discovery of an ITPR1 gene variant that was amongst
the most significant SNPs in an MDD genome-wide
association study meta-analysis (Muglia et al., 2010).
The unfolded protein response (UPR) system is a cellular
defensive mechanism activated in response to ER-related
protein misfolding. Timberlake and Dwivedi (2016)
investigated the role of the UPR system in depression. The
authors reported hippocampal upregulation of two critical
UPR markers (GRP78 and GRP94) in rats with learned
helplessness. GRP78 and GRP94 are highly involved in
apoptosis and inflammation. Evidence has implicated these
processes in the aetiology of depression (Jope et al., 2016;
Mechawar and Savitz, 2016). Additional evidence showed
that mood disorders may involve mechanisms related to
ITPR, ER stress and GSK3β signalling, albeit using an
endothelial cell degeneration model in prefrontal cortical
tissue (Kurauchi et al., 2016). Therefore, maintaining an
efficient ER stress response and UPR system may play a
role in the treatment of mood disorders.
HDAC4 was another gene identified in our study. HDAC4
regulates gene transcription by interacting with transcrip-
tion factors, signal transduction molecules and HDAC3 to
carry out many cellular functions, such as proliferation,
differentiation, neuronal survival and synaptic plasticity
(Wu et al., 2016). Hobara et al. (2010) reported increased
HDAC4 mRNA expression in patients with unipolar and
bipolar depression. In addition, Sarkar et al. (2014) repor-
ted that viral-mediated hippocampal HDAC4 over-
expression was associated with a significant increase in
depression-like behaviour in a preclinical model.
Our findings may be relevant for developing future
hypotheses involving cognitive impairments in MDD,
especially given previous evidence implicating GSK3β in
cognition (O’Leary and Nolan, 2015). For example, the ER
stress inhibitor, tauroursodeoxycholic acid, may alleviate
dysfunction of cognition (Cai et al., 2015) and preclinical
evidence has shown that ER stress-induced hippocampal
apoptosis and cognitive impairments were inhibited by
pretreatment with the ER stress inhibitor, salubrinal (Zhang
et al., 2014; Ge et al., 2015). Salubrinal has been shown to
exert neuroprotective effects (Rubovitch et al., 2015), but it
has not been tested in human clinical trials. HDAC4 may
also play a role in cognitive function (Wu et al., 2016). The
gold standard and commonly used mood stabilizers for the
treatment of bipolar disorder, lithium and divalproate, have
been implicated to exert HDAC and GSK3β inhibitory
effects. A study by Sharma and Taliyan (2015) showed that
cognitive impairments in rats treated with a low-dose
combination treatment of lithium and divalproex showed
improved spatial learning and memory.
Our findings have direct biological relevance to other
molecular targets implicated previously in mood disorder
pathophysiology, including the noncoding microRNA
precursor, miR-124 (Roy et al., 2017). Higuchi et al. (2016)
found that miR-124-mediated regulation of HDAC4 and
GSK3β hippocampal expression may have implications for
chronic stress and depression. miR-124 has been identified
as a biological mechanism underlying the effects of ery-
thropoietin treatment, which may be relevant to mood dis-
order treatment, cognitive improvements and increased
hippocampal volume (Inkster et al., 2018). Another related
molecular target is peroxisome proliferator-activated receptor
γ (PPARG), supported by evidence that PPARG activation
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improves depressive-like behaviours (Gold et al., 2013), plays
a protective role against ER stress (Gold et al., 2013) and
PPARG prosurvival activity is inhibited by HDAC4
activation (Yang et al., 2011).
Our study has several limitations. Although this work sug-
gests a potential genetic network associated with brain
changes in depression with GSK3β, it does not differentiate
between whether these MDD-specific genotype-dependent
brain structural associations are related to the pathogenesis of
MDD or occur as a consequence of disease expression. As
there is evidence showing that neuroplastic or neurodegen-
erative processes cause structural brain changes with
depression, stress and pharmacotherapy, this impact of stress,
depression and medications may influence hippocampal
morphology. We did not test whether these structural
changes are specific to major depression. We restricted our
analysis to the right hippocampus on the basis of our previous
findings (Inkster et al., 2009); however, future work could
examine both hippocampi and relevant regions in temporal
and prefrontal cortices. Both of the samples used in this
study involved recurrent MDD patients. Therefore, we
could not consider hypotheses related to early-onset MDD
or first-episode MDD to delineate disease processes across
time; for example, in first-episode MDD patients, the lit-
erature suggests that there are no hippocampal volume def-
icits (Schmaal et al., 2016) and so it remains unknown how or
whether our identified biological mechanisms would be
involved. We did not have access to high-quality data related
to age of onset or illness duration consistently across both
samples; however, the literature suggests that its correlation
with age is quite strong and so it is unlikely that it would
have impacted on our results significantly. Nonetheless, we
accept that this is a limitation of our paper. There are neu-
roimaging methodological differences for generating hippo-
campal volume measures between our current study (i.e.
FreeSurfer software was used to measure the entire volume
of the right hippocampus) that differ from our previous study
(i.e. a SPM software-based brain-wide voxel-wise cluster-
based method was used, which identified a cluster within
the right hippocampus; Inkster et al., 2009). Furthermore, we
used statistical methodologies in this study that differed
from those of our previous work (Inkster et al., 2009, 2010),
which adds complexities to interpretation of these findings
collectively.
Conclusion
Our study provides genetic evidence supporting associa-
tions between hippocampal volume and recurrent MDD,
suggesting that ER stress inhibition and HDAC4 mod-
ifications should be explored in the search for disease-
modifying therapeutic targets for depression. They also
encourage additional drug classes and medications to be
considered, and pharmacogenetic studies and clinical trials
should be designed to assist with translating these scien-
tific findings into clinical practice.
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